HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer
Recommended
HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer
In a cohort of 300 patients with HER2+ breast cancer, results of the TROIKA study demonstrate that random assignment of either HD201 or referent trastuzumab combined with standard chemotherapy over a duration of 12 weeks leads to no statistical efficacy differences.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->